NYSE:TEVAPharmaceuticals
Teva (TEVA) Stock Faces Earnings Shock Despite Strong Brand Growth
Teva Pharmaceutical Industries stock inched up about 2% to US$35.41 into the earnings reaction, which suggests a calm headline move for what is actually a noisy quarter. The real story is a sharp quarterly earnings swing into a reported net loss of US$576 million and basic earnings per share of US$0.49 loss, driven largely by acquisition related research and development charges. Behind that profit squeeze, revenue of about US$4.1b kept the top line broadly steady for a large global drug...